/
Oncology
Metastatic Solid Tumor
12
Pipeline Programs↗
7
Active Trials↗
11
Companies Involved↗
Metastatic Solid Tumor is an emerging landscape with 12 programs across 11 companies. The most active players are Coherus Oncology, Inc., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 19
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
73%
Small molecule
8 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 12 pipeline programs.
Analysis
Trial Status
10
clinical trials
Recruiting5 · 50%
Completed3 · 30%
Not yet recruiting1 · 10%
Active, not recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)